Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23600982 | 0.86 | HTR6 (0.39) | PDE5ACSNK2A1MAPTSMN1; SMN2CSNK2A2 | |
| SCHEMBL30961043 | 0.86 | MAPT (0.39) | PDE5AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL23600977 | 0.86 | MAPT (0.39) | PDE5AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL23577065 | 0.85 | PDE5A (0.36) | PDE5ACSNK2A1MAPTSMN1; SMN2CSNK2A2 | |
| SCHEMBL23577125 | 0.85 | PDE5A (0.42) | PDE5ACSNK2A1MAPTSMN1; SMN2CSNK2A2 | |
| SCHEMBL23600979 | 0.85 | EGFR (0.44) | PDE5ACSNK2A1MAPTSMN1; SMN2CSNK2A2 | |
| SCHEMBL23577499 | 0.85 | CSF1R (0.44) | MAPT | |
| SCHEMBL23576963 | 0.85 | ABCG2 (0.42) | PDE5ASMN1; SMN2 | |
| SCHEMBL23577341 | 0.85 | PDE5A (0.36) | PDE5ACSNK2A1MAPTSMN1; SMN2CSNK2A2 | |
| SCHEMBL30961070 | 0.85 | ABCG2 (0.42) | PDE5ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| EP-4081305-B1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES INC (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | PDE5A 1924/4885CSNK2A1 1221/4885MAPT 4206/4885 |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | PDE5A 1924/4885CSNK2A1 1221/4885MAPT 4206/4885 |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | PDE5A 1924/4885CSNK2A1 1221/4885MAPT 4206/4885 |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | PDE5A 1924/4885CSNK2A1 1221/4885MAPT 4206/4885 |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | PDE5A 1924/4885CSNK2A1 1221/4885MAPT 4206/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | PDE5A 1924/4885CSNK2A1 1221/4885MAPT 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.